I don't want to get too optimistic, but our Public Policy team in Washington has assembled strong, bipartisan support for the Immunosuppression bill now introduced in both the Senate and House. With each new look at the legislation, its cost is coming down, and with a Congress sorely in need of bipartisanship, this just may be our best chance ever at ensuring access to immunosuppression for the life of the allograft. Will passage of this bill make a difference for your patients? How much does cost influence your decisions about transplant candidacy? Selection of immunosuppressive regimen?
Robert S. Gaston